Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study ...

The novel extended-release formulation is expected to prevent both acute and delayed CINV for up to 5 days, improving patient compliance and convenience.

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...

The Ault PENT1040A/B/C/D family of high power injectors target PoE, gigabit-compatible applications (10/100/1,000-Mbit/s data rates) with up to 40–W power. They provide power to devices through RJ45 ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...